News Item

Jan 7, 2022
Versantis to Present at the H.C. Wainwright Bioconnect Virtual Conference

Versantis will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Mark Fitzpatrick (Chief Executive Officer), Dr. Vincent Forster (Chief Scientific Officer), and Dr. Katharina Staufer (Chief Medical Officer) will present the recent clinical achievements of Versantis' lead drug candidate, VS-01, and provide an outlook for the business and its pipeline of promising treatments for rare liver diseases and ultra-rare pediatric urea cycle disorders.

The corporate presentation will be available for viewing on-demand, starting Monday January 10th, 2022 at 7:00 am EST / 13.00 CET.

Click here to access directly Versantis' webcasted presentation: 

About Versantis

Versantis is a clinical stage biotechnology company focused on addressing the growing, un-met medical need in liver diseases. With a pipeline of drug and diagnostic product candidates to potentially address chronic and orphan acute indications, Versantis believes it can revolutionize current standard of care for patients suffering from acquired and genetic hepatic deficiencies. Versantis’ lead program, VS-01, is in clinical development as a potential first-line therapy for the timely reversal of acute-on-chronic liver failure (ACLF). It harnesses Versantis’ proprietary scavenging liposomes to extract ammonia and ACLF-related metabolites from the body and, if approved, will be the first drug to take advantage of the intraperitoneal route to potentially support the liver, kidneys and brain, the organs that most often acutely fail in cirrhotic patients. VS-01 has received orphan drug designation (ODD) from the EMA and U.S. FDA, as well as a Rare Pediatric Diseases Designation from the U.S. FDA for Urea Cycle Disorders. Founded by scientists from ETH Zurich with entrepreneurial drive, Versantis has built a team and Board of seasoned industry executives with a proven ability to advance novel therapies from the idea stage into clinical development, regulatory approval, and commercial launch. The company is headquartered in Zurich, Switzerland with an established wholly-owned U.S. subsidiary, Versantis, Inc.